Next-generation sequencing (NGS) has helped usher in a new genomic era, deepening our understanding of disease biology and accelerating research of novel, predictive biomarkers to improve patient outcomes. The adoption of NGS technology into laboratories often presents significant challenges, however, including expensive equipment and reagents, cumbersome library preparation workflows, and complex data analysis.
Enter the QuantideX NGS Portfolio: high-performance, out-of-the-box solutions for rapid library generation and push-button results interpretation via proprietary software. The assays allow for the broad detection of common DNA- and RNA-associated variants, including single nucleotide polymorphisms (SNPs), insertions/deletions (indels), gene fusions, and exon skipping events —all within a single common workflow that expedites time-to-result. Lastly, with sample QC directly integrated into the workflow, the QuantideX NGS Portfolio provides results you can trust with the ease-of-use you’ve come to expect from Asuragen.
The QuantideX® NGS DNA Hotspot 21 Kit* interrogates 46 hotspot regions within 21 genes, spanning over 1,500 genomic variants and covering approximately 80% of known variants reported within these sequences.
The QuantideX® NGS RNA Lung Cancer Kit* detects 107 known fusions, 3’/5’ imbalances associated with novel rearrangements, and MET exon skipping events implicated in lung cancer development and progression.
*For Research Use Only. Not for use in diagnostic procedures.
